NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000001407

Registered date:01/10/2008

The Efficacy and Safety of the new biologic agents (humanized anti-human Interlukin-6 receptor monoclonal antibody) on abnormal lipid metabolism and atherosclerosis for rheumatoid arthritis patients in Japan

Basic Information

Recruitment status
Health condition(s) or Problem(s) studiedRheumatoid Arthritis
Date of first enrollment2008/10/01
Target sample size120
Countries of recruitmentJapan
Study typeObservational
Intervention(s)

Outcome(s)

Primary OutcomeAdiponectin Remnant like particles-cholesterol Each type of serum cholesterol Carotid echo sonography
Secondary OutcomeDAS28 Remission rate ACR core set Total Sharp Score

Key inclusion & exclusion criteria

Age minimumNot applicable
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteriaRA patients who have serious infection patients who have history of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies patients with Primary or secondary immunodeficiency

Related Information

Contact

public contact
Name Kazuyoshi Saito
Address 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, JAPAN Japan
Telephone 093-603-1611
E-mail kazu-s@med.uoeh-u.ac.jp
Affiliation University of Occupation & Environmental Health The First Department of Internal Medicine
scientific contact
Name Yoshiya Tanaka
Address 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, JAPAN Japan
Telephone 093-603-1611
E-mail tanaka@med.uoeh-u.ac.jp
Affiliation University of Occupation & Environmental Health The First Department of Internal Medicine